Hepatocarcinogenesis in p53-deficient mice
✍ Scribed by Christopher J. Kemp
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 482 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0899-1987
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
To determine whether a constitutive p53 deficiency would enhance the rate of development of chemically induced hepatocellular carcinoma, we treated groups of wild‐type, p53‐heterozygous (+/‐), and null (‐/‐) male mice with a single dose of diethylnitrosamine at 12 d of age. Although the null mice had to be killed very early, at 15 wk of age because of the development of nonliver tumors, hemangosarcoma of the liver had already developed in two of seven mice. More detailed analysis of the wild‐type and heterozygous mice showed no difference in the number, size, or growth rate of early microscopic lesions or in the number or apparent malignancy of hepatocellular adenomas or carcinomas at later time points. Thus, germline p53 deficiency does not enhance the rate of development of diethylnitrosamine‐induced hepatocellular adenoma or carcinoma but may instead favor development of hepatic hemangiosarcoma. © 1995 Wiley‐Liss Inc.
📜 SIMILAR VOLUMES
## Abstract Livers from wild‐type and p53‐deficient mice were analyzed for the expression of cell‐cycle regulatory proteins in an attempt to determine the mechanism for the increased proliferation of liver cells in p53‐deficient mice associated with enhanced susceptibility to aflatoxin‐induced live
The major risk factors for human liver cancer: hepatitis B virus (HBV) related liver injury, male gender, aflatoxin exposure, and p53 expression, are evaluated and compared in experimental transgenic mouse models. Transgenic mice that express hepatitis B surface antigen (HBsAg) in their liver and de
The relative contribution to development of hepatocellular carcinoma of the mouse equivalent to the human p53ser249 mutation, found in human hepatocellular carcinoma associated with aflatoxin (AFB1) exposure, is compared with other major risk factors in a transgenic mouse model. Transgenic p53ser246